Neumedicines Inc.
Clinical-stage biopharmaceutical company focused on development of a recombinant human interleukin-12 therapeutic (rHuIL-12) for oncology (combination with standard-of-care therapies) and as a medical countermeasure for hematopoietic syndrome of acute radiation exposure. The company conducts preclinical and clinical development, including randomized and single-arm studies, and collaborates with academic medical centers.
Industries
Nr. of Employees
small (1-50)
Products
Recombinant human interleukin-12 therapeutic (rHuIL-12)
A recombinant interleukin-12 biologic candidate developed for use as a combination immunotherapeutic in oncology and as a medical countermeasure to mitigate hematopoietic syndrome after radiation exposure.
Recombinant human interleukin-12 therapeutic (rHuIL-12)
A recombinant interleukin-12 biologic candidate developed for use as a combination immunotherapeutic in oncology and as a medical countermeasure to mitigate hematopoietic syndrome after radiation exposure.
Services
Partnerships with academic medical centers to design and run clinical studies combining biologic therapeutics with standard-of-care treatments.
Partnerships with academic medical centers to design and run clinical studies combining biologic therapeutics with standard-of-care treatments.
Expertise Areas
- Immuno-oncology
- Clinical trial management
- Biologic (cytokine) drug development
- Hematopoiesis and radiomitigation research
Key Technologies
- Recombinant cytokine therapeutics (rHuIL-12)
- In vivo efficacy models (rodent, canine, non-human primate)
- Cytokine and chemokine assays (IFN-γ, IL-18, CXCL9/10/11)
- Pharmacokinetic/pharmacodynamic analysis
News & Updates
Presentation on clinical Phase 3 plans and emergency use authorization considerations for rHuIL-12 in pancytopenia.
Phase 2A clinical study report of rHuIL-12 in mycosis fungoides-type cutaneous T cell lymphoma combined with low-dose total skin electron beam therapy.
Clinical data describing NK cell migration, chemokine induction and receptor expression following administration of recombinant IL-12 in healthy subjects.
Publication reporting hematopoietic and immune effects after single low-dose recombinant IL-12.
Preclinical publication reporting improved survival in irradiated non-human primates treated with recombinant IL-12 in the absence of supportive care.
Presentation on clinical Phase 3 plans and emergency use authorization considerations for rHuIL-12 in pancytopenia.
Phase 2A clinical study report of rHuIL-12 in mycosis fungoides-type cutaneous T cell lymphoma combined with low-dose total skin electron beam therapy.
Clinical data describing NK cell migration, chemokine induction and receptor expression following administration of recombinant IL-12 in healthy subjects.
Publication reporting hematopoietic and immune effects after single low-dose recombinant IL-12.
Preclinical publication reporting improved survival in irradiated non-human primates treated with recombinant IL-12 in the absence of supportive care.